- Home
- ZTR vs OLMA Comparison
ZTR vs OLMA Comparison
Compare ZTR & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTR
- OLMA
- Stock Information
- Founded
- ZTR 1988
- OLMA 2006
- Country
- ZTR Australia
- OLMA United States
- Employees
- ZTR N/A
- OLMA N/A
- Industry
- ZTR Investment Managers
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- ZTR Finance
- OLMA Health Care
- Exchange
- ZTR Nasdaq
- OLMA Nasdaq
- Market Cap
- ZTR 361.7M
- OLMA 383.1M
- IPO Year
- ZTR N/A
- OLMA 2020
- Fundamental
- Price
- ZTR $5.85
- OLMA $4.99
- Analyst Decision
- ZTR
- OLMA Strong Buy
- Analyst Count
- ZTR 0
- OLMA 4
- Target Price
- ZTR N/A
- OLMA $28.33
- AVG Volume (30 Days)
- ZTR 219.4K
- OLMA 986.5K
- Earning Date
- ZTR 01-01-0001
- OLMA 03-10-2025
- Dividend Yield
- ZTR 12.09%
- OLMA N/A
- EPS Growth
- ZTR N/A
- OLMA N/A
- EPS
- ZTR N/A
- OLMA N/A
- Revenue
- ZTR N/A
- OLMA N/A
- Revenue This Year
- ZTR N/A
- OLMA N/A
- Revenue Next Year
- ZTR N/A
- OLMA N/A
- P/E Ratio
- ZTR N/A
- OLMA N/A
- Revenue Growth
- ZTR N/A
- OLMA N/A
- 52 Week Low
- ZTR $4.50
- OLMA $4.60
- 52 Week High
- ZTR $6.60
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- ZTR 43.69
- OLMA 38.98
- Support Level
- ZTR $5.79
- OLMA $4.94
- Resistance Level
- ZTR $5.91
- OLMA $5.34
- Average True Range (ATR)
- ZTR 0.08
- OLMA 0.42
- MACD
- ZTR -0.01
- OLMA -0.03
- Stochastic Oscillator
- ZTR 17.19
- OLMA 11.39
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.